

CITATION REPORT

List of articles citing

Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

DOI: 10.1161/jaha.120.016219

Journal of the American Heart Association, 2020, 9, e016219.

Source: <https://exaly.com/paper-pdf/77010064/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
348	Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID-19. 2020 , 50, 1483-1491		11
347	Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome. <i>Journal of the American Heart Association</i> , 2020 , 9, e017364	6	18
346	Angiotensin-converting enzyme 2: A protective factor in regulating disease virulence of SARS-CoV-2. 2020 , 72, 2533-2545		8
345	The Potential Role of Coagulation Factor Xa in the Pathophysiology of COVID-19: A Role for Anticoagulants as Multimodal Therapeutic Agents. 2020 , 4, e288-e299		15
344	Research Progress of Genetic Structure, Pathogenic Mechanism, Clinical Characteristics, and Potential Treatments of Coronavirus Disease 2019. 2020 , 11, 1327		3
343	COVID-19 associated complications and potential therapeutic targets. 2020 , 886, 173548		10
342	ACEIs and ARBs and Their Correlation with COVID-19: A Review. 2020 , 13, 3217-3224		15
341	COVID's Razor: RAS Imbalance, the Common Denominator Across Disparate, Unexpected Aspects of COVID-19. 2020 , 13, 3169-3192		4
340	Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities. 2020 , 116, 2197-2206		62
339	Older age and frailty are the chief predictors of mortality in COVID-19 patients admitted to an acute medical unit in a secondary care setting- a cohort study. 2020 , 20, 409		51
338	Increased Plasma Heparanase Activity in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2020 , 11, 575047	8.4	49
337	Potential Inhibitors for SARS-CoV-2 and Functional Food Components as Nutritional Supplement for COVID-19: A Review. 2020 , 75, 458-466		19
336	The Role of Smoking and Nicotine in the Transmission and Pathogenesis of COVID-19. 2020 , 375, 498-509		15
335	SARS-CoV-2 receptor networks in diabetic and COVID-19-associated kidney disease. 2020 , 98, 1502-1518		33
334	Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. 2020 , 74, 109721		63
333	Intoxication With Endogenous Angiotensin II: A COVID-19 Hypothesis. <i>Frontiers in Immunology</i> , 2020 , 11, 1472	8.4	19
332	Mild and Asymptomatic Covid-19 Infections: Implications for Maternal, Fetal, and Reproductive Health. 2020 , 2,		5

331	SARS-CoV-2 and the cardiovascular system. 2020 , 510, 311-316	4
330	An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic. 2020 , 257, 118105	30
329	Uso terapéutico de los inhibidores de la enzima convertidora de angiotensina en pacientes con COVID-19: las «dos caras de la moneda». 2020 , 27, 212-222	
328	Vascular Manifestations of COVID-19 - Thromboembolism and Microvascular Dysfunction. <i>Frontiers in Cardiovascular Medicine</i> , 2020 , 7, 598400	5-4 27
327	Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization. 2020 , 22, 2228-2237	34
326	Cardiovascular Disease and SARS-CoV-2: the Role of Host Immune Response Versus Direct Viral Injury. 2020 , 21,	2
325	Comparative analysis between the use of renin-angiotensin system antagonists and clinical outcomes of hospitalized patients with COVID-19 respiratory infection. 2020 , 155, 473-481	4
324	Understanding the Clinical Features of Coronavirus Disease 2019 From the Perspective of Aging: A Systematic Review and Meta-Analysis. 2020 , 11, 557333	8
323	Molecular dynamics simulation perception study of the binding affinity performance for main protease of SARS-CoV-2. 2020 , 1-16	9
322	Perinatal COVID-19 outcomes: evaluating the strength of current evidence. 2020 , 1-7	1
321	A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease. 2020 , 14, 1179546820977196	23
320	SARS-CoV-2 Infection in Cancer Patients: Effects on Disease Outcomes and Patient Prognosis. 2020 , 12,	9
319	Impact of COVID-19 on neurological manifestations: an overview of stroke presentation in pandemic. 2020 , 41, 2675-2679	16
318	Pathogenesis of SARS-CoV-2 induced cardiac injury from the perspective of the virus. 2020 , 147, 12-17	19
317	Neuroinvasion, neurotropic, and neuroinflammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients. 2020 , 41, 2657-2669	144
316	COVID-19: A Concern for Cardiovascular Disease Patients. 2020 , 20, 443-447	4
315	Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting. 2020 , 884, 173455	45
314	[Comparative analysis between the use of renin-angiotensin system antagonists and clinical outcomes of hospitalized patients with COVID-19 respiratory infection]. 2020 , 155, 473-481	5

313	Focus on clinical practice: angiotensin-converting enzyme 2 and corona virus disease 2019: pathophysiology and clinical implications. 2020 , 21, 630-633	7
312	Second Update for Anaesthetists on Clinical Features of COVID-19 Patients and Relevant Management. 2020 , 9,	1
311	Outcomes of COVID-19 Hospitalized Patients Previously Treated with Renin-Angiotensin System Inhibitors. 2020 , 9,	4
310	Clinical and imaging features of pediatric COVID-19. 2020 , 46, 153	8
309	Subclinical elevated B-type Natriuretic Peptide (BNP) indicates endothelial dysfunction contributing to hypoxia susceptibility in healthy individuals. 2020 , 260, 118408	3
308	Catecholamine physiology and its implications in patients with COVID-19. 2020 , 8, 978-986	19
307	Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. 2020 , 88, 106980	20
306	ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs. 2020 , 11, 5453	100
305	Therapeutic modalities and novel approaches in regenerative medicine for COVID-19. 2020 , 56, 106208	15
304	Designed variants of ACE2-Fc that decouple anti-SARS-CoV-2 activities from unwanted cardiovascular effects. 2020 , 165, 1626-1633	10
303	Cardiovascular patients in COVID-19 era, a case series, an experience from a tertiary cardiovascular center in Tehran, Iran. 2020 , 8, 2436	10
302	African League Against Rheumatism (AFLAR) preliminary recommendations on the management of rheumatic diseases during the COVID-19 pandemic. 2021 , 40, 3445-3454	8
301	Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2. 2020 , 101, 107716	40
300	Hypokalemia as a sensitive biomarker of disease severity and the requirement for invasive mechanical ventilation requirement in COVID-19 pneumonia: A case series of 306 Mediterranean patients. 2020 , 100, 449-454	31
299	Cardiovascular Complications Associated with COVID-19 and Potential Therapeutic~Strategies. 2020 , 21,	32
298	COVID-19 and the Cardiovascular System. 2020 , 43, 381-389	6
297	Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19. 2020 , 192, E1156-E1161	19
296	Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China. 2020 , 43, 1267-1276	55

295	Could Mesenchymal Stem Cell-Derived Exosomes Be a Therapeutic Option for Critically Ill COVID-19 Patients?. 2020 , 9,	11
294	COVID-19 and Comorbid Hypertension: Is ACE2 the Culprit?. 2020 , 35, 700-701	1
293	COVID-19 Outbreak: Pathogenesis, Current Therapies, and Potentials for Future Management. 2020 , 11, 563478	30
292	Low Baseline Pulmonary Levels of Cytotoxic Lymphocytes as a Predisposing Risk Factor for Severe COVID-19. 2020 , 5,	3
291	COVID-19 in adult patients with pre-existing chronic cardiac, respiratory and metabolic disease: a critical literature review with clinical recommendations. 2020 , 6, 16	34
290	MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes. 2020 , 148, 46-49	47
289	The Pathophysiology, Diagnosis and Treatment of Corona Virus Disease 2019 (COVID-19). 2020 , 35, 1-12	9
288	Neonatal and Children's Immune System and COVID-19: Biased Immune Tolerance versus Resistance Strategy. 2020 , 205, 1990-1997	12
287	Association between renin-angiotensin-aldosterone system inhibitor treatment, neutrophil-lymphocyte ratio, D-Dimer and clinical severity of COVID-19 in hospitalized patients: a multicenter, observational study. 2021 , 35, 588-597	13
286	Angiotensin-converting enzyme 2, the complement system, the kallikrein-kinin system, type-2 diabetes, interleukin-6, and their interactions regarding the complex COVID-19 pathophysiological crossroads. 2020 , 21, 1470320320979097	3
285	A potential hypothesis for 2019-nCoV infection therapy through delivery of recombinant ACE2 by red blood cell-hitchhiking. 2020 , 27,	0
284	Hypertensive Crisis in Pregnancy with COVID19: Confirmed with rt-PCR for Nasopharyngeal Swab. 2020 , 2020, 8868952	2
283	Recent updates on COVID-19: A holistic review. 2020 , 6, e05706	12
282	Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis. 2020 , 7,	22
281	Ischemic Heart Disease Pathophysiology Paradigms Overview: From Plaque Activation to Microvascular Dysfunction. 2020 , 21,	53
280	The impact of COVID-19 on vascular training. 2020 , 72, 380-381	7
279	Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2). 2020 , 57, 339-350	18
278	COVID-19, an opportunity to reevaluate the correlation between long-term effects of anthropogenic pollutants on viral epidemic/pandemic events and prevalence. 2020 , 141, 111418	83

277	Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study. 2020 , 76, e10-e12	48
276	Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. 2020 , 9,	285
275	Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far?. 2020 , 143, 417-424	69
274	COVID-19 cytokine storm: The anger of inflammation. 2020 , 133, 155151	224
273	Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications. 2020 , 256, 117905	77
272	Prognostic Value of Cardiovascular Biomarkers in COVID-19: A Review. <i>Viruses</i> , 2020 , 12,	6.2 37
271	Could the smoking gun in the fight against COVID-19 be the (rh)ACE-2?. 2020 , 56,	11
270	COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. 2020 , 22, 957-966	137
269	Pathophysiology of COVID-19: Why Children Fare Better than Adults?. 2020 , 87, 537-546	142
268	Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression. 2020 , 21, 1470320320926899	148
267	Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. 2020 , 395, 1705-1714	251
266	Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review. 2020 , 194, 105921	305
265	Targeting Nephrylsin (NEP) pathways: A potential new hope to defeat COVID-19 ghost. 2020 , 178, 114057	22
264	COVID-19 - Does This Disease Kill Due to Imbalance of the Renin Angiotensin System (RAS) Caused by Genetic and Gender Differences in the Response to Viral ACE 2 Attack?. 2020 , 29, 964-972	12
263	Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020. 2020 , 87, 431-437	12
262	Involvement of cardiovascular system as the critical point in coronavirus disease 2019 (COVID-19) prognosis and recovery. 2020 , 61, 381-395	29
261	The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors: Implications for Pharmacovigilance. 2020 , 43, 699-709	31
260	COVID-19 and comorbidities: a systematic review and meta-analysis. 2020 , 132, 749-755	88

259	COVID-19 Pandemic: Cardiovascular Complications and Future Implications. 2020 , 20, 311-324		63
258	Thoughts on the alveolar phase of COVID-19. 2020 , 319, L115-L120		50
257	A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir. 2020 , 201, 112527		52
256	What would Sérgio Ferreira say to your physician in this war against COVID-19: How about kallikrein/kinin system?. 2020 , 143, 109886		14
255	A Comparison Between Chinese Children Infected with Coronavirus Disease-2019 and with Severe Acute Respiratory Syndrome 2003. 2020 , 224, 30-36		19
254	The Prevention and Management of COVID-19: Seeking a Practical and Timely Solution. 2020 , 17,		8
253	COVID-19 and the heart: An update for clinicians. 2020 , 43, 1216-1222		18
252	Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections: Revised Ms SBMB 2020_166. 2020 , 202, 105719		72
251	Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?. 2020 , 56,		177
250	COVID-19 and the cardiovascular system: A review of current data, summary of best practices, outline of controversies, and illustrative case reports. 2020 , 226, 174-187		8
249	Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of the American Heart Association</i> , 2020 , 9, e016219	6	292
248	Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?. <i>Journal of the American Heart Association</i> , 2020 , 9, e016509	6	159
247	Overview: Systemic Inflammatory Response Derived From Lung Injury Caused by SARS-CoV-2 Infection Explains Severe Outcomes in COVID-19. <i>Frontiers in Immunology</i> , 2020 , 11, 1626	8.4	74
246	Drug targets for COVID-19 therapeutics: Ongoing global efforts. 2020 , 45, 1		54
245	The Rapid Transformation of Cardiac Surgery Practice in the Coronavirus Disease 2019 (COVID-19) Pandemic: Insights and Clinical Strategies From a Center at the Epicenter. 2020 , 110, 1108-1118		11
244	The rapid transformation of cardiac surgery practice in the coronavirus disease 2019 (COVID-19) pandemic: Insights and clinical strategies from a center at the epicenter. 2020 , 160, 937-947.e2		18
243	Review of evidence on using ACEi and ARBs in patients with hypertension and COVID-19. 2020 , 36, 1-4		3
242	The rapid transformation of cardiac surgery practice in the coronavirus disease 2019 (COVID-19) pandemic: insights and clinical strategies from a centre at the epicentre. 2020 , 58, 667-675		9

241	Reversible Encephalopathy Syndrome (PRES) in a COVID-19 patient. 2020 , 267, 3157-3160	56
240	ACE2 as a Therapeutic Target for COVID-19; its Role in Infectious Processes and Regulation by Modulators of the RAAS System. 2020 , 9,	19
239	Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review. 2020 , 81, 919	17
238	Long-term ACE Inhibitor/ARB Use Is Associated With Severe Renal Dysfunction and Acute Kidney Injury in Patients With Severe COVID-19: Results From a Referral Center Cohort in the Northeast of France. 2020 , 71, 2447-2456	33
237	Current Perspectives on Coronavirus Disease 2019 and Cardiovascular Disease: A White Paper by the Editors. <i>Journal of the American Heart Association</i> , 2020 , 9, e017013	6 38
236	Perspectives for the use of therapeutic Botulinum toxin as a multifaceted candidate drug to attenuate COVID-19. 2020 , 6, 100042	14
235	SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications. 2020 , 144, 47-53	86
234	Achieving a popliteal venous access for renal replacement therapy in critically ill COVID-19 patient in prone position. 2020 , 6, 266-268	11
233	Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus. 2020 , 164, 108166	160
232	Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications. 2020 , 41,	235
231	Renin-angiotensin-aldosterone system and COVID-19 infection. 2020 , 81, 63-67	45
230	Current status of potential therapeutic candidates for the COVID-19 crisis. 2020 , 87, 59-73	163
229	Elevated Troponin in Patients With Coronavirus Disease 2019: Possible Mechanisms. 2020 , 26, 470-475	170
228	Molecular chronicles of cytokine burst in patients with coronavirus disease 2019 (COVID-19) with cardiovascular diseases. 2021 , 161, e217-e226	6
227	Severe Acute Respiratory Syndrome Coronavirus-2 Cardiovascular Complications: Implications for Cardiothoracic Anesthesiology. 2021 , 35, 932-943	1
226	Emerging Human Coronavirus Infections (SARS, MERS, and COVID-19): Where They Are Leading Us. 2021 , 40, 5-53	13
225	Covid-19 and the cardiovascular system: a comprehensive review. 2021 , 35, 4-11	90
224	Renin-angiotensin system at the interface of COVID-19 infection. 2021 , 890, 173656	12

223	Double trouble: combined cardiovascular effects of particulate matter exposure and coronavirus disease 2019. 2021 , 117, 85-95	7
222	Mechanisms of COVID-19-induced cardiovascular disease: Is sepsis or exosome the missing link?. 2021 , 236, 3366-3382	11
221	Anti-inflammatory drugs and the renin-angiotensin-aldosterone system: Current knowledge and potential effects on early SARS-CoV-2 infection. 2021 , 291, 198190	7
220	Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. 2021 , 18, 169-193	194
219	Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator. 2021 , 11, 1-12	40
218	A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor. 2021 , 221, 107750	16
217	COVID-19 and congenital heart disease: an insight of pathophysiology and associated risks. 2021 , 31, 233-240	12
216	Overview of Targets and Potential Drugs of SARS-CoV-2 According to the Viral Replication. 2021 , 20, 49-59	12
215	Are losartan and imatinib effective against SARS-CoV2 pathogenesis? A pathophysiologic-based in silico study. 2021 , 9, 1	16
214	The Counter Regulatory Axis of the Lung Renin-Angiotensin System in Severe COVID-19: Pathophysiology and Clinical Implications. 2021 , 30, 786-794	8
213	Correlating arterial blood gas, acid-base and blood pressure abnormalities with outcomes in COVID-19 intensive care patients. 2021 , 58, 95-101	12
212	A case of malignant cerebral infarction associated with COVID-19 infection. 2021 , 35, 191-194	3
211	Safety of ACE-I and ARB medications in COVID-19: A retrospective cohort study of inpatients and outpatients in California. 2021 , 5, e8	1
210	The ACE2 as a "rescue protein" or "suspect enzyme" in COVID-19: possible application of the Engineered inactive hrsACE2 as a safer therapeutic agent in the treatment of SARS-CoV-2 infection. 2021 , 18, 495-502	4
209	Coronavirus disease (COVID-19) and the endothelium. 2021 , 205-211	
208	Health Promotion to Reduce Hypertension Patients' Vulnerability to Coronavirus Disease-19 (COVID-19). 2021 , 34, 99-102	
207	Bioinformatics and system biology approach to identify the influences of COVID-19 on cardiovascular and hypertensive comorbidities. 2021 , 22, 1387-1401	17
206	A super learner ensemble of 14 statistical learning models for predicting COVID-19 severity among patients with cardiovascular conditions. 2021 , 5, 100030	4

205	Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors and Coronavirus Disease 2019 (COVID-19). 2021 , 114, 51-56	8
204	IPG as a new method to improve the agility of the initial analysis of the inventive design. 2021 , 49, 549-562	4
203	What Is the Difference Between Observed Association and Causal Association, Signals and Evidence? Examples Related to COVID-19. 2020 , 11, 569189	0
202	Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases. 2021 , 135, 1-17	11
201	WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2.	
200	Expert Opinions on the Most Promising Treatments and Vaccine Candidates for COVID-19: Global Cross-sectional Survey of Virus Researchers in the Early Months of the Pandemic. 2021 , 7, e22483	0
199	Evaluation of Childhood COVID-19 Cases: A Retrospective Analysis. 2021 , 16, 091-098	1
198	SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19. 2021 , 17, e1008686	30
197	Prise en charge des patients atteints de maladies rhumatismales pendant la pandémie de COVID-19 : la Société Française de rhumatologie répond aux questions fréquentes posées jusqu'en mai 2020. 2021 , 88, 93-100	
196	Role of Cigarette Smoke on Angiotensin-Converting Enzyme-2 Protein Membrane Expression in Bronchial Epithelial Cells Using an Air-Liquid Interface Model. 2021 , 12, 652102	4
195	Fatality and risk features for prognosis in COVID-19 according to the care approach - a retrospective cohort study. 2021 , 16, e0248869	3
194	RAAS Blockade and COVID-19: Mechanistic Modeling of Mas and AT1 Receptor Occupancy as Indicators of Pro-Inflammatory and Anti-Inflammatory Balance. 2021 , 109, 1092-1103	0
193	Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19. 2021 , 45, 251-259	25
192	Potential therapeutic and pharmacological strategies for SARS-CoV2. 2021 , 51, 1-16	9
191	SARS-CoV-2 as an inflammatory cardiovascular disease: current knowledge and future challenges. 2021 , 17, 1277-1291	1
190	Revisiting Pleiotropic Effects of Type I Interferons: Rationale for Its Prophylactic and Therapeutic Use Against SARS-CoV-2. <i>Frontiers in Immunology</i> , 2021 , 12, 655528	8.4 5
189	Cardiovascular Disease and COVID-19: Insight From Cases With Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 629958	5.4 3
188	The Renin-Angiotensin System, Hypertension, and SARS-CoV-2 Infection: a Review. 2021 , 23, 17	1

187	COVID-19: Risk Factors Associated with Infectivity and Severity. 2021 , 93, e13039			14
186	Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension. 2021 , 36, S123-S131			4
185	Immunobiology and nanotherapeutics of severe acute respiratory syndrome 2 (SARS-CoV-2): a current update. 2021 , 53, 559-580			5
184	Excess mortality in Greece during 2020: the role of COVID-19 and cardiovascular disease. 2021 , 62, 378-380			1
183	SARS-CoV-2 Viral Entry Proteins in Hyperandrogenemic Female Mice: Implications for Women with PCOS and COVID-19. 2021 , 22,			6
182	Diabetes Mellitus and COVID-19: Associations and Possible Mechanisms. 2021 , 2021, 7394378			8
181	An Updated Review on SARS-CoV-2 Main Proteinase (M): Protein Structure and Small-Molecule Inhibitors. 2021 , 21, 442-460			12
180	Myopericarditis Associated with COVID-19 in a Pediatric Patient with Kidney Failure Receiving Hemodialysis. 2021 , 10,			2
179	Associations Between the Use of Renin-Angiotensin System Inhibitors and the Risks of Severe COVID-19 and Mortality in COVID-19 Patients With Hypertension: A Meta-Analysis of Observational Studies. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 609857	5.4		3
178	Human cell receptors: potential drug targets to combat COVID-19. 2021 , 53, 813-842			6
177	Is multisystem inflammatory syndrome related with coronavirus disease 2019, Kawasaki disease, and angiotensin-converting enzyme 2 in children?. 2021 , 64, 225-226			0
176	ACE2-based decoy receptors for SARS coronavirus 2. 2021 , 89, 1065-1078			4
175	Immunological and physiopathological approach of COVID-19 in pregnancy. 2021 , 304, 39-57			8
174	Association of ACEi/ARB Use and Clinical Outcomes of COVID-19 Patients With Hypertension. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 577398	5.4		1
173	Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity. 2021 , 137, 111363			18
172	A brief molecular insight of COVID-19: epidemiology, clinical manifestation, molecular mechanism, cellular tropism and immuno-pathogenesis. 2021 , 476, 3987-4002			2
171	Variants in ACE2; potential influences on virus infection and COVID-19 severity. 2021 , 90, 104773			28
170	Gastrointestinal manifestations of human immunodeficiency virus and coronavirus disease 2019: Understanding the intersecting regions between the two epidemics. 2021 , 22, 75-87			0

169	Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention. 2021 , 73, 1539-1550	4
168	Do Changes in Expression Affect SARS-CoV-2 Virulence and Related Complications: A Closer Look into Membrane-Bound and Soluble Forms. 2021 , 22,	6
167	The Impetus of COVID -19 in Multiple Organ Affliction Apart from Respiratory Infection: Pathogenesis, Diagnostic Measures and Current Treatment Strategy. 2021 , 21, 514-526	5
166	Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021. 2021 , 12, 659577	15
165	COVID-19 after emergency coronary artery bypass grafting: features of the postoperative course and prognosis. 2021 , 44-51	
164	Ayurveda botanicals in COVID-19 management: An in silico multi-target approach. 2021 , 16, e0248479	17
163	Why does SARS-CoV-2 hit in different ways? Host genetic factors can influence the acquisition or the course of COVID-19. 2021 , 64, 104227	8
162	Mutations and polymorphisms in genes involved in the infections by covid 19: a review. 2021 , 23, 101062	3
161	Role of ACE 2 and Vitamin D: The Two Players in Global Fight against COVID-19 Pandemic.	
160	New perspectives on angiotensin-converting enzyme 2 and its related diseases. 2021 , 12, 839-854	1
159	Pulmonary Involvement in COVID-19 and "Long Covid" The Morbidity, Complications and Sequelae. 2021 , 5, 034-048	1
158	COVID-19 and hyperglycaemic emergencies: perspectives from a developing country. 1-7	0
157	The SARS-CoV-2 pandemic is associated with increased severity of presentation of childhood onset type 1 diabetes mellitus: A multi-centre study of the first COVID-19 wave. 2021 , 38, e14640	13
156	Serum biomarkers of cardiovascular complications in COVID-19. 2021 , 26, 4456	3
155	New-Onset Diabetes with Ketoacidosis Precipitated by COVID-19 in Children: A Report of Two Cases. 2021 , 2021, 5545258	2
154	Hypothesis for renin-angiotensin inhibitor mitigation of COVID-19. 2021 , 152, 110609	1
153	Prognostic Accuracy of Cardiovascular Disease Biomarkers in Patients with COVID-19: A Diagnostic Test Accuracy Meta-Analysis.. 2021 , 16, 1-14	
152	Risks of emergency vascular surgery in COVID-19 patients. 2021 , 28,	1

151	Acute Pericarditis Due to SARS-COV-2 in a Kidney Transplant Recipient. <i>Cureus</i> , 2021 , 13, e16547	1.2	
150	The Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Is Associated with the Recovered Ejection Fraction in Patients with Dilated Cardiomyopathy. 2021 , 62, 801-810	2	
149	Triangle of cytokine storm, central nervous system involvement, and viral infection in COVID-19: the role of sFasL and neuropilin-1. 2021 ,	4	
148	Quantifying arrhythmic long QT effects of hydroxychloroquine and azithromycin with whole-heart optical mapping and simulations. 2021 , 2, 394-404	6	
147	Renin-angiotensin system modulators in COVID-19 patients with hypertension: friend or foe?. 2021 , 1-10	2	
146	The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target. 2021 , 43, 177-196	1	
145	Neurological manifestations of COVID-19 in patients: from path physiology to therapy. 2021 , 42, 4867-4879	0	
144	Retinal manifestations in patients with SARS-CoV-2 infection and pathogenetic implications: a systematic review. 2021 , 1	7	
143	Cytokine storm and histopathological findings in 60 cases of COVID-19-related death: from viral load research to immunohistochemical quantification of major players IL-1 β , IL-6, IL-15 and TNF- α . 2021 , 1	6	
142	Analytical methods for the identification of micro/nano metals in e-cigarette emission samples: a review. 2021 , 75, 1-12	0	
141	Classical and Counter-Regulatory Renin-Angiotensin System: Potential Key Roles in COVID-19 Pathophysiology. 2021 , 3, 1060-1074	2	
140	Cardiac biomarkers, cardiac injury, and comorbidities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. 2021 , 9, 1071-1100	8	
139	Sex Differences in Association Between Anti-Hypertensive Medications and Risk of COVID-19 in Middle-Aged and Older Adults. 2021 , 38, 921-930	1	
138	Neuropsychiatric manifestations of COVID-19, potential neurotropic mechanisms, and therapeutic interventions. 2021 , 11, 499	9	
137	Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline. 2021 , 27, 515-523	1	
136	The Cardiac Effects of COVID-19: Review of articles. 2021 , 47, 100981	1	
135	Impact of COVID-19 infection on the cardiovascular system: An evidence-based analysis of risk factors and outcomes. 2021 , 35, 437-448	1	
134	COVID-19-Induced Mesenteric Thrombosis. <i>Cureus</i> , 2021 , 13, e12953	1.2	6

133	The ancient cardioprotective mechanisms of ACE2 bestow SARS-CoV-2 with a wide host range.	
132	Research Progress on the Cardiac Injury from ACE2 Targeting in SARS-CoV-2 Infection. 2021 , 11,	0
131	Immunological and cardio-vascular pathologies associated with SARS-CoV-2 infection in golden syrian hamster.	6
130	One health disparities and COVID-19. 2021 , 9, 70-77	6
129	Prone positioning as an emerging tool in the care provided to patients infected with COVID-19: a scoping review. 2021 , 29, e3397	4
128	Evidence of Coronavirus (CoV) Pathogenesis and Emerging Pathogen SARS-CoV-2 in the Nervous System: A Review on Neurological Impairments and Manifestations. 2021 , 71, 2192-2209	32
127	Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm. 2021 , 39, 707-722	15
126	Angiotensin converting enzyme-2 as therapeutic target in COVID-19. 2020 , 14, 637-639	36
125	The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the "Ariadne's thread" for the "labyrinth" of COVID-19. 2020 , 61, 31-33	3
124	Sars-CoV-2 and black population: ACE2 as shield or blade?. 2020 , 84, 104361	18
123	Drugs acting on renin angiotensin system and use in ill patients with COVID-19. 2020 , 75, 319-325	4
122	RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies. 2020 , 135, 106805	34
121	Covid-19: the renin-angiotensin system imbalance hypothesis. 2020 , 134, 1259-1264	49
120	Proliferation of Papers and Preprints During the Coronavirus Disease 2019 Pandemic: Progress or Problems With Peer Review?. 2020 , 27, 418-426	19
119	Baseline use of angiotensin-converting enzyme inhibitor/AT1 blocker and outcomes in hospitalized coronavirus disease 2019 African-American patients. 2020 , 38, 2537-2541	14
118	The Impact of SARS-CoV-2 on the Human Immune System and Microbiome. 2021 , 3, 14-21	3
117	ACE inhibition and cardiometabolic risk factors, lung and gene expression, and plasma ACE2 levels: a Mendelian randomization study. 2020 , 7, 200958	6
116	ACE inhibition and cardiometabolic risk factors, lung ACE2 and TMPRSS2 gene expression, and plasma ACE2 levels: a Mendelian randomization study.	4

115	A systematic review and meta-analysis to evaluate the clinical outcomes in COVID -19 patients on angiotensin converting enzyme inhibitors or angiotensin receptor blockers.	2
114	Low baseline pulmonary levels of cytotoxic lymphocytes as a predisposing risk factor for severe COVID-19. 2020 ,	3
113	Robust ACE2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is not increased by ACE inhibitors or angiotensin receptor blockers. 2020 ,	18
112	Increased plasma heparanase activity in COVID-19 patients.	4
111	Diagnostic technology for COVID-19: comparative evaluation of antigen and serology-based SARS-CoV-2 immunoassays, and contact tracing solutions for potential use as at-home products.	2
110	A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease.	1
109	A Potential Role for Photobiomodulation Therapy in Disease Treatment and Prevention in the Era of COVID-19. 2020 , 11, 1352-1362	1
108	Serious Conditions in COVID-19 Accompanied With a Feature of Metabolic Syndrome. 2020 , 12, 273-275	1
107	Insights into Potential Mechanisms of Injury and Treatment Targets in COVID-19, SARS-Cov-2 Infection. 2020 , 5,	4
106	Debatable points of using angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in patients with COVID-19. 2020 , 19, 2580	4
105	SARS-CoV-2 infection of the nervous system: A review of the literature on neurological involvement in novel coronavirus disease-(COVID-19). 2020 , 20, 283-292	26
104	[Role of age, comorbidity and renin- angiotensin-aldosterone system in COVID-19. Effects of ACE inhibitors and angiotensin receptor blockers]. 2020 , 60, 4-9	4
103	Newly-onset type 1 diabetes mellitus precipitated by COVID-19 in an 8-month-old infant. 2020 , 91, ahead of print	10
102	Hypertension and sex related differences in mortality of COVID-19 infection: A systematic review and Meta-analysis. 2020 , 4, 037-043	1
101	Management of liver diseases during the pandemic of coronavirus disease-19. 2020 , 26, 243-250	3
100	The factors predicting pneumonia in COVID-19 patients: preliminary results from a university hospital in Turkey. 2020 , 50, 1810-1816	2
99	Renin-Angiotensin System Implications to COVID-19 Comorbidities. 2020 , 8, 148-151	1
98	Possible protective role of 17 β -estradiol against COVID-19. 2020 , 1, 38-48	10

- 97 Histopathological findings in the advanced natural evolution of the SARS-CoV-2 infection. **2020**, 61, 209-218 11
- 96 SARS-CoV-2 Infection Presenting with Hyperglycemia and Ketosis: A Case Series of Three Diabetic Patients. **2020**, 24, 1141-1142 5
- 95 Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment. **2020**, 53, 400-412 32
- 94 Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19. **2020**, 14, 161-170 6
- 93 Immune Thrombocytopenia Purpura Secondary to COVID-19. *Cureus*, **2020**, 12, e9083 1.2 13
- 92 Research Status of SARS-CoV-2 on Cardiovascular System Injury in Children. **2021**, 36, 685-690
- 91 Does Hypertension Alone Increase Mortality In Young Hypertensive Patients With COVID-19? Single Center Retrospective Study Of 100 Patients.
- 90 WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2. **2021**, 9, e12262 1
- 89 Challenges in Pharmacological Management of Cardiovascular Diseases in Covid-19: do Benefits Outweigh Risks?. **2020**, 33, 404-411
- 88 Cardiovascular Impacts of COVID-19 Pandemic: From Presentation to Management: Current and Future Perspectives. **2020**, 11, em00739 6
- 87 Data Analysis of COVID-19 THE GREAT EPIDEMIC OF THE YEAR 2020 (Preprint).
- 86 Diabetes mellitus and COVID-19. How are they connected? Current strategy of fight. **2020**, 26, 304-311 1
- 85 Expert Opinions on the Most Promising Treatments and Vaccine Candidates for COVID-19: Global Cross-sectional Survey of Virus Researchers in the Early Months of the Pandemic (Preprint).
- 84 CORONAVIRUS: Pathology, Immunology and Therapies.. 1-17
- 83 Designed Variants of ACE2-Fc that Decouple Anti-SARS-CoV-2 Activities from Unwanted Cardiovascular Effects. 0
- 82 SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review. **2021**, 3
- 81 Will Remdesivir Reshape Cardiovascular Practice in COVID 19 Era?. **2021**, 30, 155-159 1
- 80 . **2020**, 192, E1816-E1822

- 79 Could ischemic colitis be the first manifestation of COVID-19? A case report. **2020**, 68, 231-234
- 78 The efficacy and safety of Xuebijing injection for corona virus disease 2019: A protocol for a systematic review and meta-analysis. **2020**, 99, e23401 1
- 77 Losartan promotes cell survival following SARS-CoV-2 infection in vitro.
- 76 Myocarditis Associated with Coronavirus Disease 2019 (COVID-19) in a Pediatric Patient. **2020**, 10, 226-232
- 75 Clinical presentation, complications, and outcomes of hospitalized COVID-19 patients in an academic center with a centralized palliative care consult service. **2021**, 4, e423 0
- 74 Increased complications of COVID-19 in people with cardiovascular disease: Role of the renin-angiotensin-aldosterone system (RAAS) dysregulation. **2021**, 351, 109738 4
- 73 Cardiovascular Complications Associated with COVID-19 Infection. **2020**, 2,
- 72 High-performance computing will assist experiments in recovery from COVID-19. **2020**, 1, 355-358
- 71 Primer on the Pathogenesis of Severe COVID-19: Part Two. 0
- 70 Massive Pulmonary Thromboembolism in Patients with COVID-19; Report of Three Cases. **2020**, 8, e58 5
- 69 [Epidemiological features and mechanism of coronavirus disease 2019 in children]. **2021**, 23, 420-424
- 68 COVID-19 and its implication for venous thromboembolism. **2020**, 27, 481-484
- 67 COVID-19, the Pandemic of the Century and Its Impact on Cardiovascular Diseases. **2021**, 1, 233-258 1
- 66 COVID-19 Infection and Myocarditis: A State-of-the-Art Systematic Review. **2021**, 12, 21501327211056800 6
- 65 Effect of renin-angiotensin system blocker on COVID-19 in young patients with hypertension.. **2022**, ,
- 64 Intricate relationship between SARS-CoV-2-induced shedding and cytokine storm generation: A signaling inflammatory pathway augmenting COVID-19.. **2022**, 100011 2
- 63 Gender-related response of body systems in COVID-19 affects outcome. **2022**, 11, 1020-1036 1
- 62 Golden Syrian hamster as a model to study cardiovascular complications associated with SARS-CoV-2 infection.. **2022**, 11, 0

61	Role of Genetic Variants and Host Polymorphisms on COVID-19: From Viral Entrance Mechanisms to Immunological Reactions.. 2022 ,		1
60	COVID-19 and atherosclerosis. 2022 , Publish Ahead of Print,		1
59	Polymorphisms in ACE, ACE2, AGTR1 genes and severity of COVID-19 disease.. 2022 , 17, e0263140		4
58	Cardiovascular System and SARS-CoV-2: Etiology, Physiopathology and Clinical Presentation: A Systematic Review.		0
57	Fatal association of COVID-19 and acute type A aortic dissection.. 2022 , 10, e05617		1
56	Risk Factors Associated With COVID-19 Symptoms and Potential Vertical Transmission During Pregnancy: A Retrospective Cohort Study.. <i>Cureus</i> , 2022 , 14, e22900	1.2	1
55	Angiotensin-converting enzyme 2 and Transmembrane protease serine 2 in female and male patients with end-stage kidney disease.. 2022 , e13786		0
54	Discovery of a new generation of angiotensin receptor blocking drugs: receptor mechanisms and in silico binding to enzymes relevant to covid-19.. 2022 ,		2
53	David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors.. 2022 , 14, 2057832		2
52	ELEVATED INTERLEUKIN β AND FERRITIN LEVELS EXACERBATE SEVERITY OF 2019 NOVEL CORONAVIRUS DISEASE (COVID-19): A PILOT STUDY. 2021 , 16-19		
51	Angiotensin-converting enzyme 2 as a potential therapeutic target for COVID-19: A review.. 2021 ,		2
50	Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19.. 2021 , 82, 43		1
49	Evolutionary pathways to SARS-CoV-2 resistance are opened and closed by epistasis acting on ACE2.. 2021 , 19, e3001510		0
48	Lung ultrasound in ruling out COVID-19 pneumonia in the ED: a multicentre prospective sensitivity study.. <i>Emergency Medicine Journal</i> , 2021 ,	1.5	2
47	Neurological and psychological manifestations and consequences of an acute severe acute respiratory syndrome coronavirus 2 infection. <i>Rossiiskii Meditsinskii Zhurnal: Organ Ministerstva Zdravookhraneniia RSFSR</i> , 2021 , 27, 407-418	0.1	
46	Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis.. <i>Circulation</i> , 2022 , 145, 1123-1139	16.7	13
45	COVID-19 and acute myocardial injury: Stem cell driven tissue remodeling in COVID-19 infection. 2022 , 111-124		
44	Soluble ACE2 and angiotensin II levels are modulated in hypertensive COVID-19 patients treated with different antihypertension drugs.. <i>Blood Pressure</i> , 2022 , 31, 80-90	1.7	0

43	Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy. <i>Viruses</i> , 2022 , 14, 1029	6.2	1
42	Association of Congenital and Acquired Cardiovascular Conditions With COVID-19 Severity Among Pediatric Patients in the US.. <i>JAMA Network Open</i> , 2022 , 5, e2211967	10.4	0
41	Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy. <i>Frontiers in Immunology</i> , 2022 , 13,	8.4	4
40	The chimera of S1 and N proteins of SARS-CoV-2: can it be a potential vaccine candidate for COVID-19?. <i>Expert Review of Vaccines</i> ,	5.2	
39	Assessment of mutations on RBD in the Spike protein of SARS-CoV-2 Alpha, Delta and Omicron variants. <i>Scientific Reports</i> , 2022 , 12,	4.9	2
38	The SARS-CoV-2 Spike Protein Activates the Epidermal Growth Factor Receptor-Mediated Signaling.		
37	Cardiac Complications of COVID-19 in Low-Risk Patients. <i>Viruses</i> , 2022 , 14, 1322	6.2	0
36	An ADAM17-Neutralizing Antibody Reduces Inflammation and Mortality While Increasing Viral Burden in a COVID-19 Mouse Model. <i>Frontiers in Immunology</i> , 13,	8.4	0
35	Clinical and genetic predictors of cardiovascular events as the risk of an unfavorable course and outcomes of novel coronavirus infection. <i>HERALD of North-Western State Medical University Named After I I Mechnikov</i> , 2022 , 14, 5-16	0.2	0
34	Experimental Models of SARS-COV-2 Infection in the Central Nervous System. <i>Journal of Central Nervous System Disease</i> , 2022 , 14, 117957352211022	4.4	
33	Focal Myocarditis As the First Sign in the Presentation of a COVID-19 Infection: A Case Report. <i>Cureus</i> , 2022 ,	1.2	
32	Cardiorenal Syndrome in COVID-19 Patients: A Systematic Review. <i>Frontiers in Cardiovascular Medicine</i> , 9,	5.4	0
31	A Comprehensive Analysis of Myocarditis in Formerly Healthy Individuals Following SARS-CoV-2 Vaccination (COVID-19 Immunization). <i>Cureus</i> , 2022 ,	1.2	0
30	Actions of Novel Angiotensin Receptor Blocking Drugs, Bisartans, Relevant for COVID-19 Therapy: Biased Agonism at Angiotensin Receptors and the Beneficial Effects of Neprilysin in the Renin Angiotensin System. 2022 , 27, 4854		
29	The effect of coronavirus infection on QT and QTc intervals of hospitalized patients in Qazvin, Iran.		
28	Evaluation of Hemodynamic Status of the COVID-19 Patients Under Anesthesia. 2022 , In Press,		
27	COVID-19 and cognitive impairment: neuroinvasive and blood-brain barrier dysfunction. 2022 , 19,		2
26	Renal, Cardiac, Neurological, Cutaneous and Coagulopathic Long-term Manifestations of COVID-19 after Recovery; A review. 1-29		0

25	Gut Microbiota Dynamics in Relation to Long-COVID-19 Syndrome: Role of Probiotics to Combat Psychiatric Complications. 2022 , 12, 912	1
24	Post-COVID-19 investor psychology and individual investment decision: A moderating role of information availability. 13,	0
23	Inactivation of SARS-CoV-2 Spike Protein Pseudotyped Virus Infection Using ACE2-Tethered Gold Nanorods under Near-Infrared Laser Irradiation.	0
22	Molecular-Level Targets for the Development of Therapies Against Coronavirus Diseases. 2021 , 69-84	0
21	Narrative Review of New Insight into the Influence of the COVID-19 Pandemic on Cardiovascular Care. 2022 , 58, 1554	0
20	Misleading Advertising of Health-Related Products in Ecuador during the COVID-19 Pandemic. 2022 , 10, 91	0
19	Cereals as a Source of Bioactive Compounds with Anti-Hypertensive Activity and Their Intake in Times of COVID-19. 2022 , 11, 3231	0
18	COVID-19 Related Organ Damage. 2022 , 12, 813-823	0
17	Respiratory issues in patients with multiple sclerosis as a risk factor during SARS-CoV-2 infection: a potential role for exercise.	0
16	Renin-Angiotensin-Aldosterone axis inhibition improves outcome of diabetic patients with chronic hypertension and COVID-19: An Iranian perspective. 2022 , 11, 109	0
15	Cardiovascular Complications of Viral Respiratory Infections and COVID-19. 2023 , 11, 71	0
14	Atherosclerosis, Cardiovascular Disorders and COVID-19: Comorbid Pathogenesis. 2023 , 13, 478	2
13	COVID-19: Diabetes Perspective Pathophysiology and Management. 2023 , 12, 184	1
12	COVID-19 and pediatrics Phylogeny, pathology, and pathogenesis of SARS-CoV-2. 2023 , 23-40	0
11	Complicaciones Cardiovasculares asociadas a infecci3n por SARS-CoV-2. Revisi3n Sistem3tica. 51,	0
10	Emerging role of microRNAs and long non-coding RNAs in COVID-19 with implications to therapeutics. 2023 , 861, 147232	0
9	The Role of Immunity in the Pathogenesis of SARS-CoV-2 Infection and in the Protection Generated by COVID-19 Vaccines in Different Age Groups. 2023 , 12, 329	0
8	Cell transplantation for COVID-19 treatment: transmission of stem stomal (mesenchimal) cells. 2020 , 15, 10-19	0

- 7 Effect of B12 and folate deficiency in hypomethylation of Angiotensin I converting enzyme 2 gene and severity of disease among the acute respiratory distress syndrome patients. **2023**, 37, ○
- 6 The potential role of SARS-CoV-2 infection in acute coronary syndrome and type 2 myocardial infarction (T2MI): Intertwining spread. **2023**, 11, ○
- 5 Myocarditis and Pericarditis following COVID-19 Vaccination in Thailand. **2023**, 11, 749 ○
- 4 The SARS-CoV-2 Spike Protein Activates the Epidermal Growth Factor Receptor-Mediated Signaling. **2023**, 11, 768 ○
- 3 A Review of Pathology and Analysis of Approaches to Easing Kidney Disease Impact: Host-Pathogen Communication and Biomedical Visualization Perspective. **2023**, 41-57 ○
- 2 Associations of arterial hypertension and the severity of the course of a new coronavirus infection. **2023**, 19, 19-27 ○
- 1 Gender Susceptibility and Comorbidities in COVID-19 Headache. **2023**, 109-120 ○